Health Care [ 4/12 ] | Biotechnology [ 17/74 ]
NASDAQ | Common Stock
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company.
It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.
Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology.
The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute.
Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases.
Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease.
The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 27, 24 | -0.92 Decreased by -299.52% | - |
| Aug 28, 24 | -0.08 Increased by +43.94% | -0.09 Increased by +11.11% |
| May 10, 24 | -0.08 Increased by +78.36% | - |
| Mar 26, 24 | -0.11 Increased by +95.75% | -0.12 Increased by +8.33% |
| Nov 9, 23 | -0.23 Decreased by -285.91% | -0.01 Decreased by -2.20 K% |
| Aug 11, 23 | -0.14 Increased by +42.92% | -0.20 Increased by +28.65% |
| May 15, 23 | -0.39 Increased by +23.53% | -0.28 Decreased by -39.29% |
| Mar 29, 23 | -2.59 Decreased by -3.14 K% | -0.08 Decreased by -3.14 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -1.83 M Increased by +70.79% | - - |
| Jun 30, 24 | 1.50 M Increased by +N/A% | -3.04 M Increased by +2.50% | Decreased by -202.11% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.00 M Increased by +67.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.50 M Increased by +N/A% | -3.76 M Decreased by -32.11% | Decreased by -250.06% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -6.26 M Decreased by -9.29% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.11 M Increased by +68.24% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.26 M Increased by +100.00% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -2.84 M Decreased by -0.11% | Decreased by N/A% Decreased by N/A% |